Antigens produced from IRES-dependent translation of the polycistronic meloe mRNA (MELOE-1, -2 and possibly others) may thus represent a new class of tumor antigens in that they seem to be both tumor-specific and lineage specific and thus ideal targets for immunotherapy of melanoma. This evidence concerns the gene HDAC4-AS2 and neoplasm.